Aficamten clinical trials
Also written CK-3773274.
How each study uses aficamten is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the aficamten studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 19 Dec 2025 · MYQORZO · NDA 219083 (FDA, Drugs@FDA)
- European Union
- 12 Feb 2026 · Myqorzo · EMEA/H/C/006228 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
12 studies that test it; most in 2023 (4)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2020 | 1 |
| 2021 | 2 |
| 2022 | 1 |
| 2023 | 4 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 11 · Other 1
Cytokinetics (8) · Corxel Pharmaceuticals (2) · Bayer (1) · Oregon Health and Science University (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test aficamten.
- Dec 2026Mavacamten to Aficamten Transition in Patients With Obstructive Hypertrophic CardiomyopathyPhase 4 · Oregon Health and Science University
Studies
Open first, then newest update. How each study uses aficamten is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 12
- Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten in Adults With HCMEnrolling by invitationPhase 2/3CytokineticsNCT04848506Written as Aficamten (5 - 20 mg)
- Mavacamten to Aficamten Transition in Patients With Obstructive Hypertrophic CardiomyopathyRecruitingPhase 4Oregon Health and Science UniversityNCT07600177Written as Aficamten
- A Study to Learn More About How Well Aficamten Works in Japanese Participants With Symptomatic Obstructive Hypertrophic CardiomyopathyActive, not recruitingPhase 3BayerNCT07023341Written as BAY3723113
- A Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)Active, not recruitingPhase 3CytokineticsNCT06081894Written as Aficamten
- A Study to Evaluate the Effect of Aficamten in Pediatric Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM).Active, not recruitingPhase 2/3CytokineticsNCT06412666Written as Aficamten
- Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol Succinate in Adults With Symptomatic oHCMCompletedPhase 3CytokineticsNCT05767346Written as Aficamten (CK-3773274) (5 mg, 10 mg, 15 mg and 20 mg)
- Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic oHCMCompletedPhase 3CytokineticsNCT05186818Written as Aficamten (5 mg, 10 mg, 15 mg, and 20 mg)
- Dose-finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CK-3773274 in Adults With Hypertrophic CardiomyopathyCompletedPhase 2CytokineticsNCT04219826Written as CK-3773274 (5 - 15 mg)
- An Open-Label Study of Aficamten for Chinese Patients With Symptomatic oHCMCompletedPhase 3Corxel PharmaceuticalsNCT06116968Written as Aficamten
- Safety, Tolerability and Pharmacokinetics Study of CK-3773274CompletedPhase 1Corxel PharmaceuticalsNCT04783766Written as CK-3773274
- A Single and Multiple Ascending Dose Study of CK-3773274 in Healthy Adult SubjectsCompletedPhase 1CytokineticsNCT03767855Written as CK-3773274 - Granules in Capsule
- Study to Evaluate the Effect of Aficamten Administration on QT/QTc IntervalCompletedPhase 1CytokineticsNCT05924815Written as Aficamten
Codes
What other systems call aficamten · ClinicalTrials.gg INT002121
- MeSH (NLM) C000731669aficamtenOne source NLM
- UNII (FDA) B1I77MH6K1AFICAMTENConfirmed FDA, NLM, Wikidata
- Wikidata Q106438207aficamtenConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C179072AficamtenOne source FDA
- DrugBank DB18490One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000731669 | aficamten | One source NLM |
| UNII (FDA) | B1I77MH6K1 | AFICAMTEN | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q106438207 | aficamten | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C179072 | Aficamten | One source FDA |
| DrugBank | DB18490 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.